Navigation Links
Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives
Date:2/1/2011

exemption of any securities under federal and state securities laws.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel®, the Company's lead pain product candidate, has completed a Phase 3 clinical trial and utilizes the Transdel™ technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications. The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; the Company's ability to obtain regulatory approval to market Ketotransdel; the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform and the Company's ability to complete a strategic alternative. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
4. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
5. Transdel Pharmaceuticals Announces Management Reorganization
6. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
7. Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... AUSTIN, Texas , Oct. 22, 2014 ... announced they have entered into a license and ... to target cancers. PhosImmune possesses technology ... the surfaces of tumor cells in association with ... from proteins that play a role in malignancy, ...
Breaking Medicine Technology:Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/25/2014)... New York (PRWEB) October 25, 2014 ... mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against ... underway in U.S. District Court, Southern District of ... Summary Judgment on Punitive Damages in a group ... In a ruling issued on October 21st, U.S. ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... (HealthDay News) -- Researchers who discovered antibiotics in ... cause for concern. The use of antibiotics ... human consumption contribute to the development of antibiotic-resistant ... information from the study. Each year in ... million people and kill about 23,000, according to ...
(Date:10/25/2014)... By Randy Dotinga ... -- As more genetic tests are developed that spot increased ... would be more proactive about getting screened. But a ... does not change behavior: People who found out their genes ... than people with average risk to get screened. "It ...
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville Community Health Center ... fair ¡Vive tu vida! Get Up! Get Moving!®. The event ... health and wellness for people of all ages and all ... public, will be held at Dean Porter Park, 501 E. ... , “¡Vive tu Vida! Get Up! Get Moving!® helps ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... ... ... -- At a private reception held last Thursday evening, the Minneapolis-St. Paul Business Journal unveiled ... Marketing , a full-service marketing firm based in St. Paul, earned the No. 35 spot ...
... Safe Tables Our Priority survey demonstrates need for better ... Oct. 30 A survey of state health departments ... that the response and investigation of outbreaks varies greatly ... The survey was commissioned by the Produce Safety Project ...
... around right after procedure cuts conception rate, study found ... lie flat for 15 minutes after being artificially inseminated ... suggests. , "Allowing women treated for subfertility with IUI ... a 50 percent higher chance at conceiving," said Inge ...
... for those thrown off schedule by Daylight Saving Time ... of sleep you,ll get in most parts of the country ... Daylight Saving Time could spell trouble for your body clock, ... director of the sleep disorders research program in the division ...
... (NYSE: AGP ) today announced that net income for the ... share, versus $37.9 million, or $0.71 per diluted share, for the ... with the preliminary earnings range that the Company issued on ... associated with the onset of what appears to be a severe ...
... 30 First Choice Health Services, Inc. today announced that ... a compilation of the top-performing home health agencies in the ... of agencies and further highlights the top 100 and top ... performance measures in quality outcomes, quality improvement, and financial performance. ...
Cached Medicine News:Health News:Imagewrks Marketing Named Among Top 50 Fastest Growing Private Companies in Minnesota 2Health News:Survey of State Health Departments Underscores Gaps in Foodborne Illness Response 2Health News:Survey of State Health Departments Underscores Gaps in Foodborne Illness Response 3Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:When Clocks Change, Body May Need Time to Adjust 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 2Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 3Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 4Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 5Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 6Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 7Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 8Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 9Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 10Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 11Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 12Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 13Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 14Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 15Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 16Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 17Health News:AMERIGROUP Reports Q3 Net Income of $22.5 Million or $0.43 per Diluted Share 18Health News:First Choice Health Services, Inc. Named to 2009 HomeCare Elite as a Top Home Health Care Provider 2Health News:First Choice Health Services, Inc. Named to 2009 HomeCare Elite as a Top Home Health Care Provider 3
The Optronics MicroFire is an easy to use versatile 2-Megapixel color microscope camera with Firewire connectivity. The camera mounts easily on your microscope with a C-mount adapter and is the perfe...
Rubella IgM ELISA....
H. pylori IgG ELISA....
Mumps IgG ELISA....
Medicine Products: